AIDS Therapies

Results of Combination Therapy Study in Pregnant Women and Newborns Reported

Published in Women's Health Weekly, February 19th, 2000

Agouron Pharmaceuticals, Inc. announced results from the Pediatric AIDS Clinical Trials Group (PACTG) study 353 of the HIV protease inhibitor Viracept (nelfinavir mesylate) in combination therapy specifically in pregnant women, and the impact of gestational and postpartum treatment on HIV infection on mothers and newborns.

Results were presented at the 7th Conference on Retroviruses and Opportunistic Infections, held January 30 - February 2, 2000, in San Francisco, California.

In this open-label study, HIV infected pregnant women ranging from 14 to 34 weeks of gestation were enrolled and received oral doses of 750 mg Viracept (nelfinavir mesylate)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2000-02-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry